Found 123 articles for: "treatment"
Nordic European Countries Atopic Dermatitis (NECAD) I: Importance of Concordance With Skincare for Atopic Dermatitis
October 2026 | Volume 25 | Issue 10 | Original Article | 949 | Copyright © October 2026
Background: Atopic dermatitis (AD) is a chronic disease with a dysfunctional skin barrier, requiring continuous management to reduce symptoms and prevent flares. Topical treatmen...
Read MoreDifferences in Atopic Dermatitis Comorbidity and Treatment Patterns by Race
October 2026 | Volume 25 | Issue 10 | Editorials | 978 | Copyright © October 2026
Clinical Evidence of Skin Improvements With a Biologically Active Multimodal Topical Skin Treatment
September 2026 | Volume 25 | Issue 9 | Original Article | 814 | Copyright © September 2026
Background: Antiaging skin treatments are continuously in development to meet the needs of an aging population and counteract cosmetic effects of glucagon-like peptide-1 receptor...
Read MoreTreatment Adherence in Patients With Acne Vulgaris: A Narrative Review
September 2026 | Volume 25 | Issue 9 | Original Article | 821 | Copyright © September 2026
Background: Acne vulgaris is a common dermatologic condition often requiring treatment using multiple mechanisms of action over a long time course to adequately clear symptoms. H...
Read MoreDifferences in Keloid and Hypertrophic Scar Treatment Patterns by Race
September 2026 | Volume 25 | Issue 9 | Editorials | e81 | Copyright © September 2026
Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Acne: Pooled Analysis by Age and Sex
August 2026 | Volume 25 | Issue 8 | Original Article | 708 | Copyright © August 2026
Background: Acne pathophysiology and presentation may differ by patient age or sex. In clinical trials, clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel...
Read MoreLatin America Cutaneous Oncology Management (LACOM) II: A Practical Algorithm for Managing Skin Toxicities in Oncology Patients
July 2026 | Volume 25 | Issue 7 | Original Article | 621 | Copyright © July 2026
Background: Anticancer treatments are associated with cutaneous adverse events (cAEs) that can severely impact patients' quality of life (QoL) and interfere with treatment outcom...
Read MoreCutaneous Adverse Effects of Hormonal and HER2-Targeted Therapies in Breast Cancer Patients: A Case Series
July 2026 | Volume 25 | Issue 7 | Case Reports | 659 | Copyright © July 2026
Background: Aromatase inhibitors (AIs) and anti-HER2 therapies improve breast cancer survival, but dermatologic adverse events (dAEs) are underrecognized despite affecting qualit...
Read MoreTrends in Fluorouracil and Calcipotriene Utilization for Actinic Keratosis
June 2026 | Volume 25 | Issue 6 | Editorials | e56 | Copyright © June 2026
Efficacy, Safety, and Real-World Aspects of Janus Kinase Inhibitors to Treat Patients With Alopecia Areata
March 2026 | Volume 25 | Issue 3 | Original Article | 204 | Copyright © March 2026
Alopecia areata (AA) is an autoimmune disease characterized by nonscarring hair loss on the scalp and body, leading to a reduced quality of life and psychosocial burden for patients. The only US ...
Read MoreBrodalumab's 8-Year Journey in Plaque Psoriasis: Insights into Efficacy, Safety, and Real-World Evidence
March 2026 | Volume 25 | Issue 3 | Original Article | 211 | Copyright © March 2026
Background: Plaque psoriasis is a chronic immune-mediated disease driven by proinflammatory cytokines. Brodalumab--a recombinant, human monoclonal antibody that functions as an i...
Read MoreExpert Consensus on Advanced Topical Nonsteroidal Therapies for Chronic Hand Eczema
March 2026 | Volume 25 | Issue 3 | Original Article | 228 | Copyright © March 2026
Background: Chronic hand eczema (CHE) is a common, heterogeneous inflammatory skin disease associated with substantial symptom burden, impaired hand function, reduced quality of ...
Read MoreTopical Efinaconazole 10% for Onychomycosis: Pooled Phase 3 Analysis in White, Black, and Asian Participants
January 2026 | Volume 25 | Issue 1 | Original Article | 67 | Copyright © January 2026
Background: Topical efinaconazole 10% solution has demonstrated efficacy and safety in two phase 3 trials of onychomycosis. As clinical data for onychomycosis treatments are limi...
Read MoreA Randomized, Controlled, Split-Face, Double-Blind Study Comparing Topical Malassezin to Hydroquinone 4% for Melasma
January 2026 | Volume 25 | Issue 1 | Original Article | 25 | Copyright © January 2026
Background: Previous studies have documented the capacity of malassezin to brighten the skin. It represents a novel agent for the treatment of hyperpigmentation.GLP-1 Receptor Agonists in Hidradenitis Suppurativa: A Novel Therapeutic Approach for Hidradenitis Suppurativa and Its Comorbidities
December 2025 | Volume 24 | Issue 12 | Original Article | 1174 | Copyright © December 2025
Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder associated with many comorbidities, including obesity, diabetes, cardiovascular risk factors, me...
Read MoreAn Open-Label, Single-Center Proof of Concept Study Evaluating the Efficacy and Safety of Tirzepatide for Moderate to Severe Hidradenitis Suppurativa
December 2025 | Volume 24 | Issue 12 | Original Article | 1246 | Copyright © December 2025
Background: Hidradenitis suppurativa (HS) is a chronic inflammatory disease associated with obesity and metabolic dysregulation. Current therapies yield variable benefits and do ...
Read MorePerspectives and Practice Patterns of Dermatologists Using Laser Hair Removal for Hidradenitis Suppurativa
December 2025 | Volume 24 | Issue 12 | Editorials | e71 | Copyright © December 2025
The Current Landscape of Treatment of Warts
December 2025 | Volume 24 | Issue 12 | Original Article | 1208 | Copyright © December 2025
Warts have bothered people since the early Greek and Roman empires.5 For centuries, people have studied causes of and treatments for these irritating tumors. In recent history, treatme...
Read MoreResolution of Lichen Simplex Chronicus With Nemolizumab: A Case Report
December 2025 | Volume 24 | Issue 12 | Case Reports | 1252 | Copyright © December 2025
Introduction: Lichen simplex chronicus is a debilitating condition characterized by lichenified skin secondary to intractable itch. Lichen simplex chronicus is challenging to tre...
Read MoreScar Wars: A Review of Topical Scar Therapies
December 2025 | Volume 24 | Issue 12 | Features | 1265 | Copyright © December 2025
© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
